SCHEMBL4987626

SCHEMBL4987626

ON=C(Nc1ccc(F)c(Cl)c1)c1nonc1Cn1nnnc1-c1ccc(F)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT5B P51692 1/20 0.43
ALDH1A1 P00352 2/20 0.38
HPGD P15428 1/20 0.38
MAPT P10636 6/20 0.37
TP53 P04637 3/20 0.37
LMNA P02545 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.35
HTT P42858 2/20 0.35
MEN1 O00255 6/20 0.34
KMT2A Q03164 6/20 0.34
PLA2G1B P04054 1/20 0.34
GAA P10253 1/20 0.34
ATG4B Q9Y4P1 1/20 0.34
THRB P10828 1/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
IDO1 P14902 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4987615 1.00 STAT5B (0.43) STAT5BALDH1A1HPGDMAPTTP53
SCHEMBL5631222 0.93 SMN1; SMN2 (0.38) STAT5BALDH1A1MAPTTP53L3MBTL1
SCHEMBL5631227 0.93 SMN1; SMN2 (0.38) STAT5BALDH1A1MAPTTP53L3MBTL1
SCHEMBL14462670 0.88 STAT5B (0.43) STAT5BALDH1A1HPGDMAPTTP53
SCHEMBL5630817 0.88 MEN1 (0.38) MAPTLMNAL3MBTL1HTTMEN1
SCHEMBL5630814 0.88 MEN1 (0.38) MAPTLMNAL3MBTL1HTTMEN1
SCHEMBL4983553 0.87 IDO1 (0.39) ALDH1A1MAPTL3MBTL1HTTMEN1
SCHEMBL5631701 0.87 IDO1 (0.39) ALDH1A1MAPTL3MBTL1HTTMEN1
SCHEMBL4983463 0.85 HDAC6 (0.39) ALDH1A1MAPTTP53LMNAL3MBTL1
SCHEMBL4983469 0.85 HDAC6 (0.39) ALDH1A1MAPTTP53LMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8951536-B2 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION (US) 2015-02-10 US claimed
US-20130177590-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2013-07-11 US claimed
EP-1971583-A2 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE Incyte Corporation (US) 2008-09-24 EP claimed
US-20070185165-A1 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION 2007-08-09 US claimed
WO-2007075598-A2 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2007-07-05 WO claimed
EP-1971583-B1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORP (US) 2015-03-25 EP disclosed
US-8951536-B2 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION (US) 2015-02-10 US disclosed
US-8951536-B2 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION (US) 2015-02-10 US disclosed
US-20130177590-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2013-07-11 US disclosed
US-20130177590-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2013-07-11 US disclosed
US-8450351-B2 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION (US) 2013-05-28 US disclosed
US-8450351-B2 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION (US) 2013-05-28 US disclosed
US-20070185165-A1 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION 2007-08-09 US disclosed
US-20070185165-A1 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130177590-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE IDO1, IDO2, HNMT STAT5B 2646/4885ALDH1A1 1216/4885HPGD 43/4885
US-20070185165-A1 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase IDO1, IDO2, HNMT STAT5B 2646/4885ALDH1A1 1216/4885HPGD 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.